News release
TOKYO, JAPAN - March 29, 2022 - Terumo Corporation (TSE: 4543) today announced that it will implement large-scale solar panels on the premises of Terumo Vietnam factory in Hanoi city which produces products for the Cardiac and Vascular Company. The installation is scheduled to be completed in FY2022 starting April 1, 2022. With the solar panels and by utilizing a Tradable Green Certificate, the factory will reduce the amount of CO2 (Carbon dioxide) emissions and all the electricity used at the factory will be derived from renewable energy.
Terumo commits to achieve carbon neutrality*2 for greenhouse gas emission (Scope 1 and 2) by 2040. Terumo also has been tackling with reducing the environmental impact through reducing CO2 emission and waste, making effective use of natural resources, as well as developing environmentally friendly products. Through these activities, Terumo will work towards shrinking the global issue of climate change.
- *1 International Renewable Energy Certificate(I-REC) is a standard to certify the renewable origin of electricity and is certified and issued by The International REC Standard Foundation, a non-profit organization, according to "the rule book and the tracking system based on it".
*2 Carbon neutrality means having a balance between emitting carbon and absorbing carbon.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.